Business Central for the Pharmaceutical Industry — What You Need to Know

Microsoft Dynamics 365 Business Central is used by pharmaceutical, cosmetics, and chemical manufacturers across Europe and North America. It is not the dominant ERP in large-batch pharmaceutical production — SAP remains the market leader there — but for mid-market regulated manufacturers, BC offers a commercially viable platform that can be configured and validated to meet GxP requirements.

This article describes what BC covers natively for regulated pharma, where the gaps are, and how organisations typically address those gaps. It is written from the perspective of a consultant who has implemented and validated BC in regulated environments, not from a vendor's product perspective.

Why mid-market pharma uses Business Central

The primary reasons are cost and maintainability. SAP implementation and ongoing support costs are prohibitive for manufacturers with fewer than several hundred users. Legacy systems — Dynamics NAV, older versions of Axapta, or industry-specific platforms built on obsolete technology — reach end of life and require replacement.

BC offers a modern SaaS platform with automatic updates managed by Microsoft, a large certified partner ecosystem, a structured AppSource extension marketplace, and a total cost of ownership that is accessible to mid-market organisations. It integrates with Microsoft 365, Azure, and a range of quality management and laboratory systems through standard API connectors.

What standard Business Central covers for GxP

Standard BC without customisation provides several capabilities that are directly relevant to GxP compliance:

Item tracking: BC's item tracking module handles lot numbers, serial numbers, and expiry dates at the item level. Lot tracking can be configured to require lot assignment on all inbound and outbound movements, enabling forward and backward traceability across the supply chain.

Approval workflows: BC includes a configurable approval workflow engine. Workflows can be built for purchase order approvals, quality hold releases, deviation acknowledgements, and other GxP decision points. Each approval step is recorded with user identity and timestamp.

Change Log: BC's Change Log captures field-level data changes on configured tables. This is the foundation of the audit trail for GxP-relevant records.

Permission sets: BC's permission system allows granular access control by object type (tables, pages, reports, codeunits). Properly configured permission sets implement the principle of least privilege.

Microsoft Entra ID integration: BC SaaS uses Entra ID for authentication, providing single sign-on, multi-factor authentication, and individual user identity — all prerequisites for Part 11 and Annex 11 compliance.

What standard BC does not cover natively

Standard BC does not include a batch record system. The batch manufacturing record — the document that captures the complete production history of a pharmaceutical batch — is not a native BC concept. In a regulated pharma environment, the batch record is typically managed in a dedicated quality management system or a specialised ERP extension.

Standard BC does not include a built-in QC inspection module with pass/fail disposition and hold management. Basic quality inspection functionality can be approximated using BC's warehouse management and approval workflows, but it does not meet the requirements of a regulated QC workflow without extension.

Standard BC does not include deviation, CAPA, or change control management as native modules. These processes are typically managed in a dedicated QMS system that is integrated with BC, or through a specialised AppSource extension.

AppSource extensions that address the gaps

YAVEON ProBatch: the most widely implemented extension for pharmaceutical batch management in BC. Adds a full electronic batch record, in-process controls, batch classification, and GxP-aligned audit trails. Validated and CE-marked. Available on AppSource.

Continia Document Capture: adds document management and automated data capture. Used for managing supplier certificates of analysis, regulatory correspondence, and incoming quality documents.

For QMS functionality — deviation, CAPA, change control — most regulated BC implementations integrate with a dedicated QMS platform (Veeva, MasterControl, or similar) via API rather than attempting to replicate this functionality in BC.

Practical implementation sequence for regulated pharma

The implementation sequence matters. Attempting to validate a system that is still under active configuration is a common cause of validation delays and rework.

A practical sequence is: requirements gathering and URS development; system configuration and extension deployment; validation protocol authoring; validation execution (IQ, OQ, PQ); deviation resolution; validation closure and VSR approval. Change control goes live at the same time as the system.

Quality involvement must begin at the requirements stage, not at the testing stage. QA sign-off on the URS is a prerequisite for a defensible validation.

What auditors look for in a BC-based pharma environment

Inspectors reviewing a BC implementation in a pharmaceutical manufacturer typically focus on: evidence that the system was validated (VSR and supporting documentation); that the Change Log is configured and protected for GxP-relevant tables; that access control is implemented with individual accounts and least-privilege permissions; that lot traceability can be demonstrated end-to-end; that changes to the system go through documented change control; and that the organisation has a procedure for managing BC SaaS updates within a validated environment.

Download the Business Central for pharmaceutical industry guide as a PDF using the link below.